Entrada Therapeutics TRDA Cash Flow Statement (2020-2026)

NASDAQ TRDA
$7.06 -0.11 (-1.53%)
As of: Sep 4, 2026 · 2:19 PM EDT
Reported Financials

Entrada Therapeutics Quarterly Cash Flow Statement

Periods 24 quarters
Latest Jun 2026

Entrada Therapeutics reported cash from operations of -$32.46M and free cash flow of -$32.47M for the quarter ended Jun 2026, down 10.1% year over year. This cash flow statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-14.43M-18.45M-21.67M-23.18M-25.14M-24.63M-6.72M-25.93M35.46M-9.50M23.50M54.99M-13.99M1.10M-17.35M-43.10M-44.18M-39.16M-39.72M-42.76M
Share-based Compensation
0.58M1.46M32.99M-28.68M2.71M2.88M2.75M74.83M3.73M4.62M4.86M4.70M5.09M5.05M5.12M4.36M4.74M5.15M
Deferred Taxes
-0.22M0.06M
Cash from Operations
-14.07M-20.54M-20.99M-18.01M-27.48M-27.30M203.40M-35.09M-24.49M-4.01M-25.52M39.83M-24.27M-31.61M-38.51M-29.49M-28.31M-32.20M-41.70M-32.46M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
-0.14M-0.14M0.03M0.10M0.24M1.69M1.85M2.00M2.04M2.26M3.21M2.51M1.34M0.96M0.74M0.63M0.55M0.45M
Change in Working Capital
Change in Account Payables
0.08M-1.03M2.06M1.54M-2.91M4.59M0.53M-4.38M-1.36M2.41M-0.66M-0.89M-0.31M2.85M-1.91M-0.32M1.31M-0.88M0.64M0.82M
Change in Accured Expenses
2.06M1.82M-1.53M0.73M6.90M-4.34M4.11M-5.05M2.80M1.96M-2.52M1.62M3.04M-0.42M-5.46M4.31M3.74M2.15M-5.95M1.27M
Change in Taxes
7.36M-7.36M4.02M1.83M-1.74M-1.86M-1.58M0.14M-0.80M0.62M-0.62M
Other Working Capital Changes
0.66M6.28M1.67M-5.14M15.49M2.00M211.58M-14.43M-38.21M-18.97M17.89M-87.02M-16.97M-33.72M-18.51M-0.77M-0.42M-0.12M2.46M-4.85M
Investing Activities
Capital Expenditures
0.81M1.32M0.59M0.78M0.81M2.16M8.63M0.68M2.44M-0.19M0.84M-2.88M4.57M0.64M1.14M0.28M-0.17M-0.21M0.04M0.01M
Change in Acquisitions & Divestments
1.71M25.00M30.00M19.50M63.00M28.39M74.50M108.54M123.92M87.36M83.31M118.50M85.95M50.63M75.50M47.38M38.86M58.88M
Cash from Investing Activities
-0.81M-1.32M-181.53M24.23M-10.13M18.79M-40.44M-113.26M-3.74M19.04M26.15M-24.38M-82.93M53.37M4.78M33.80M49.11M29.12M26.99M54.95M
Financing Activities
Other financing activities
0.11M190.34M0.05M0.01M0.06M0.16M0.13M0.26M0.37M0.43M0.21M1.10M0.38M1.09M0.35M0.02M0.01M0.08M0.10M0.22M
Change in Capital Stock
Net Shares Issued and Repurchased
2.31M
Net Equity Issued and Repurchased
19.41M100.00M-0.39M
Misc.
Cash from Financing Activities
0.11M190.75M0.05M0.01M0.06M0.36M19.54M0.44M0.37M0.69M0.21M101.37M-0.01M1.40M0.35M0.34M0.01M0.19M0.10M0.35M
Change in Cash
-14.78M168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.64M20.80M-2.89M-14.61M22.84M
Free Cash Flow
-14.88M-21.86M-21.59M-18.78M-28.29M-29.46M194.77M-35.77M-26.93M-3.82M-26.36M42.71M-28.83M-32.24M-39.65M-29.76M-28.14M-32.00M-41.74M-32.47M
Net Cash Flow
-14.78M168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.64M20.80M-2.89M-14.61M22.84M